Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Xeris Pharmaceuticals

Xeris Pharmaceuticals
2005 FOUNDED
PUBLIC STATUS
101-200 EMPLOYEES
XERS STOCK SYMBOL
$12.49 SHARE PRICE (As of Wednesday Closing)
Description

Xeris Pharmaceuticals Inc is a specialty pharmaceutical company leveraging its novel non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize ready-to-use injectable and infusible drug formulations. Its pipeline products are Diazepam, Pramlintide-Insulin, Self-Administered Glucagon, Continuous Glucagon, and others.

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Other Healthcare Technology Systems
Stock Exchange
NAS
Primary Office
  • 180 North LaSalle Street
  • Suite 1800
  • Chicago, IL 60601
  • United States

+1 (844) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Xeris Pharmaceuticals’s full profile, request a free trial.

Xeris Pharmaceuticals Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$8.67 - $27.98 $336M $12.45 -$5.48 245K 26.9M

Xeris Pharmaceuticals Financials Summary

In Thousands,
USD
TTM
31-Mar-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 189,700 410,666
Revenue 2,450 2,465 1,556 1,075
EBITDA (72,221) (59,046) (26,451) (13,096)
Net Income (73,450) (60,080) (26,554) (13,209)
Total Assets 160,970 120,028 44,998 33,533
Total Debt 32,141 31,890 0 47
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Xeris Pharmaceuticals Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Xeris Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook

Xeris Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore Xeris Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

Xeris Pharmaceuticals Competitors (1)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
00000000 Formerly VC-backed Valencia, CA 000 00000 000000000 00000
To view this company’s complete list of competitors, request access »

Xeris Pharmaceuticals Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Xeris Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook

Xeris Pharmaceuticals Executive Team (10)

Name Title Board
Seat
Contact
Info
Paul Edick Chief Executive Officer, President & Chairman
Barry Deutsch Chief Financial Officer
John Shannon Chief Operating Officer
Steven Prestrelski Ph.D Co-Founder & Chief Scientific Officer
John Kinzell Ph.D Co-Founder & Advisory Board Member

4 Former Executives

You’re viewing 5 of 10 executives. Get the full list »

Xeris Pharmaceuticals Board Members (13)

Name Representing Role Since Contact
Info
BJ Bormann Ph.D Self Independent, Non-executive Board Member 000 0000
Dawn Halkuff Self Independent, Non-executive Board Member 000 0000
Jeffrey Sherman MD Self Independent, Non-executive Board Member 000 0000
John Schmid Self Independent, Non-executive Board Member 000 0000
Jonathan Rigby Self Board Member 000 0000

3 Former Board Members

You’re viewing 5 of 13 board members. Get the full list »